Your Guide to Understanding Azoospermia

What causes azoospermia?

Azoospermia can result from several overlapping factors. The most frequently described causes include genetic mutations or Y chromosome microdeletions, hormonal imbalance, infections, immunological problems, prior chemotherapy or radiotherapy, and environmental or idiopathic factors. Because the underlying reason changes both prognosis and treatment planning, detailed classification is essential.

• Obstructive azoospermia: sperm production exists, but a blockage prevents sperm from entering the ejaculate.
• Non-obstructive azoospermia: the issue is related to impaired production, maturation arrest, or inadequate spermatogenesis inside the testis.

Why is Micro-TESE being reconsidered?

Micro-TESE has long been used as a surgical sperm retrieval method, but the reported success rate is generally around 30 to 40%. For many patients, especially those in whom no sperm is found, the procedure does not solve the underlying biological problem. Repeated invasive interventions may also damage sperm-producing areas of the testis and can affect future testicular function.

For this reason, a growing treatment philosophy favors “biological restoration first, surgery later,” especially in selected NOA patients who may still have spermatid-stage germ cells present in the testis.

Current scientific discussion increasingly focuses not only on finding sperm surgically, but also on whether immature reproductive cells can be supported biologically and guided toward maturation. In this context, the L-HIS Protocol is presented as a new-generation approach designed to reduce reliance on invasive procedures and prioritize biological restoration.

What is L-HIS Protocol in Turkey?

L-HIS Protocol in Turkey is a treatment model that shifts the focus from surgical retrieval to biological restoration. Its main idea is that even when mature sperm are not detected, younger sperm cells such as spermatids may still be present. With a personalized program using hormonal optimization together with phytotherapy support, these immature cells may be encouraged to mature and become usable for IVF-ICSI.

Phases of L-HIS Protocol

1. Phase 1: Molecular triggering and hormonal optimization (weeks 0-12). The goal is to create the most favorable hormonal environment for spermatogenesis, including testosterone optimization, aromatase inhibition when appropriate, and FSH-based support for Sertoli cell function.
2. Phase 2: Maturation support (weeks 12-16). Hormonal support continues and ejaculate screening begins. In resistant cases, advanced protein-targeted options such as SPO11 or SYCP3-directed approaches may be considered under appropriate conditions.
3. Phase 3: Intensive ejaculate screening (weeks 16-24+). Rare haploid cells are searched through a multi-stage laboratory process described as the “Sarsma Technique.”

Initial consultation and diagnosis

Our treatment process begins with a comprehensive initial consultation. During this consultation, our specialists thoroughly evaluate the patient's medical history and conduct a physical examination. Various tests are performed to confirm the diagnosis of azoospermia:

• Semen analysis: The first step involves analyzing the semen to determine whether any sperm cells are present in the ejaculate.
• Hormone tests: Hormone levels, particularly those of testosterone and FSH, which play a critical role in sperm production, are measured.
• Genetic testing: If necessary, genetic tests are conducted to identify potential genetic disorders that could be causing azoospermia.
• Imaging tests: Techniques such as ultrasound may be used to detect any structural abnormalities in the testes and reproductive tracts.

L-HIS Method: Our innovative treatment approach

Unlike traditional treatment methods, L-HIS Method Turkey we apply at our clinic has yielded positive results in patients with non-obstructive azoospermia.

• Treatment process: L-HIS Method is a long-term treatment protocol that lasts between 6 to 24 months. During this period, a combination of hormonal therapy and phytotherapy is used to encourage stem cells to develop into mature sperm cells.
• Success rates: We have achieved positive results in 70% of patients treated with this method, representing a significant advancement for those who previously had no sperm.
• A Revolutionary option for patients: The L-HIS Method is a revolutionary treatment option for patients with azoospermia, giving them the chance to achieve biological fatherhood.

Follow-up and monitoring

Throughout each phase of the treatment, we closely monitor our patients' progress and make adjustments to the treatment plan as needed. This includes:

• Regular check-ups: Patients are required to visit our clinic at regular intervals for check-ups. During these visits, hormone levels and sperm production are monitored.
• Evaluating treatment response: Semen analysis is repeated to evaluate the response to treatment, and adjustments are made to hormone therapy as necessary.
• Support services: Psychological support and counseling services are also available to our patients during the treatment process. Maintaining morale and motivation is crucial during long-term treatment.

The treatment process is designed as a monitored pathway rather than a one-time intervention. Baseline tests generally include FSH, LH, total testosterone, estradiol, liver function tests such as ALT and AST, and lipid profile. These are rechecked at weeks 4, 8, and 12 to assess both safety and whether the intended hormonal effect is being achieved. A central target is to maintain the testosterone to estradiol ratio above 10.

Clinical follow-up is also staged. After medication planning, patients are typically reviewed around day 45 and again around day 75 to assess development and update treatment decisions.

How does the protocol support maturation?

The protocol is built on three core biological principles. First, intratesticular testosterone is optimized, since sperm production requires concentrations far above normal serum levels. Second, the STRA8 pathway is targeted as a molecular key that helps immature cells enter meiosis and continue maturation. Third, Sertoli cells are supported, often through FSH-based hormonal strategy, because they provide the structural and nutritional scaffold required for developing germ cells.

Assisted reproductive techniques (ART)

At the end of the treatment process, assisted reproductive techniques may be applied for patients from whom sperm have been obtained:

• ICSI (Intracytoplasmic Sperm Injection): The sperm cells obtained are combined with the egg cell in a laboratory setting. This method allows men with azoospermia to achieve biological fatherhood.
• Freezing and storage: Sperm cells obtained during treatment can be frozen and stored for future use if necessary.

Who may be suitable for treatment?

The protocol is primarily presented for non-obstructive azoospermia and for patients who previously underwent unsuccessful Micro-TESE. Candidate groups described in the source material include:

• patients with azoospermia confirmed by at least two semen analyses and evidence of spermatids,
• patients with maturation arrest or hypospermatogenesis on histopathology,
• selected men with Klinefelter syndrome who retain residual testicular function,
• patients with AzF-c or AzF-c+d microdeletions that still preserve spermatid production potential,
• patients with post-chemotherapy or post-radiotherapy recovery evidence,
• idiopathic NOA patients with detectable inhibin B despite high FSH,
• men between 18 and 55 years of age with acceptable liver function tests.

Who is generally not considered suitable?

• patients with complete AzF-a or AzF-b deletions or total AzF loss,
• patients with complete Sertoli Cell Only histology and no detectable spermatids after prior failed surgery,
• patients with serious liver dysfunction or active liver disease,
• patients with psychiatric contraindications to parts of the medication plan.

Pregnancy expectations and IVF use

Turkey Azoospermia treatment model does not primarily aim for natural conception. Instead, once mature sperm or Sd4-level cells are obtained, assisted reproductive treatment such as IVF with ICSI is typically required. Reported pregnancy potential is approximately 40 to 45% when mature sperm are available and around 20% when fertilization is attempted with Sd4-level cells.

Questions and answers

Conclusion

The L-HIS Protocol represents a modern, minimally invasive shift in azoospermia care. Rather than relying exclusively on surgery, it focuses on cellular development, hormonal balance, and structured laboratory follow-up. For carefully selected NOA patients, especially those with prior failed surgical retrieval, this approach offers a meaningful new framework of hope centered on biological restoration.